Literature DB >> 26379867

Lymphocyte CD64 increased in patients with chronic HBV infection.

Hao Feng1, Jie Yin1, Ya-Ping Han2, Xiao-Ying Zhou2, Guo-Xin Zhang2.   

Abstract

CD64 was up-regulated in infection diseases, but there was no report about the change of CD64 in chronic hepatitis B virus (HBV) infection. The purpose of this study was to determine whether there was a dynamic change of CD 64 index and to judge the value to antiviral treatment. 96 CHB patients were enrolled and selected 33 healthy adults as control. We detected the level of CD64, found the level of CD64 were significantly increased in chronic HBV infection patients, especially the lymphocyte CD64 (8.12 ± 0.23 vs. 6.25 ± 0.27; P < 0.001). Further, we proved CD64 index was increased in various stages of chronic HBV infection. ROC curve analysis showed the level of lymphocyte CD64 had higher AUC value than neutrophil or monocyte. Then we monitor longitudinally the impact of the treatment with interferon-α and found that the suppression of viral replication induced by interferon-α resulted in a decrease in CD64 index. In conclusion, this study showed that CD64 index was increased in chronic HBV infection patients and changed with the course of disease, the therapy of interferon-α would correct it, and analysis prompted that the level of lymphocyte CD64 would be more suitable for as a biomarker to judge the condition of chronic HBV infection and the curative effect of interferon-α treatment.

Entities:  

Keywords:  CD64; Hepatitis B; cirrhosis; hepatocellular carcinoma

Year:  2015        PMID: 26379867      PMCID: PMC4565250     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  17 in total

1.  Chronic hepatitis B: update 2009.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

Review 2.  Hepatitis B virus infection.

Authors:  Christian Trépo; Henry L Y Chan; Anna Lok
Journal:  Lancet       Date:  2014-06-18       Impact factor: 79.321

3.  Prevention of hepatitis B in China: achievements and challenges.

Authors:  Feng-Min Lu; Hui Zhuang
Journal:  Chin Med J (Engl)       Date:  2009-12-20       Impact factor: 2.628

4.  Epstein-Barr virus-related MTX-LPD in rheumatoid arthritis patients exhibits a viral pattern of the CD64 and CD35 expression on neutrophils: three case reports.

Authors:  Sho Mokuda; Tatsuhiko Miyazaki; Yukari Saeki; Junya Masumoto; Masamoto Kanno; Kiyoshi Takasugi
Journal:  Mod Rheumatol       Date:  2014-02-05       Impact factor: 3.023

Review 5.  The novel applications of the quantitative analysis of neutrophil cell surface FcgammaRI (CD64) to the diagnosis of infectious and inflammatory diseases.

Authors:  Jari Nuutila
Journal:  Curr Opin Infect Dis       Date:  2010-06       Impact factor: 4.915

Review 6.  Treatment with interferons (including pegylated interferons) in patients with hepatitis B.

Authors:  W Graham Cooksley
Journal:  Semin Liver Dis       Date:  2004       Impact factor: 6.115

7.  Serum cytokine profile in patients with hepatitis B e antigen-negative chronic active hepatitis B and inactive hepatitis B virus carriers.

Authors:  Dimitra Dimitropoulou; Marina Karakantza; Georgios L Theodorou; Lydia Leonidou; Stelios F Assimakopoulos; Athanasia Mouzaki; Charalambos A Gogos
Journal:  World J Gastrointest Pathophysiol       Date:  2013-02-15

8.  CD64 index provides simple and predictive testing for detection and monitoring of sepsis and bacterial infection in hospital patients.

Authors:  M Icardi; Y Erickson; S Kilborn; B Stewart; B Grief; G Scharnweber
Journal:  J Clin Microbiol       Date:  2009-10-21       Impact factor: 5.948

9.  Antibody-directed complement-mediated cytotoxicity to hepatocytes from patients with chronic hepatitis B.

Authors:  T I Michalak; J Y Lau; B M McFarlane; G J Alexander; A L Eddleston; R Williams
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

10.  Human cytomegalovirus Fcγ binding proteins gp34 and gp68 antagonize Fcγ receptors I, II and III.

Authors:  Eugenia Corrales-Aguilar; Mirko Trilling; Katja Hunold; Manuela Fiedler; Vu Thuy Khanh Le; Henrike Reinhard; Katrin Ehrhardt; Eva Mercé-Maldonado; Enver Aliyev; Albert Zimmermann; David C Johnson; Hartmut Hengel
Journal:  PLoS Pathog       Date:  2014-05-15       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.